



## **Aldeyra Therapeutics to Host Conference Call and Webcast to Announce Top-Line Results from Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Disease**

December 2, 2019

*Event scheduled for 8:00 a.m. ET Tuesday, December 3, 2019*

LEXINGTON, Mass.--(BUSINESS WIRE)--Dec. 2, 2019-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call and webcast at 8:00 a.m. ET Tuesday, December 3, 2019, to provide top-line results from Part 1 of the adaptive Phase 3 RENEW Trial of topical ocular reproxalap in patients with dry eye disease.

The dial-in numbers are (866) 211-4098 for domestic callers and (647) 689-6613 for international callers. The Conference ID is 1592481. A live audio webcast of the conference call will also be available on the Investor Relations section of the Aldeyra Therapeutics website at <https://ir.aldeyra.com>. Presentation slides will be available on the investor relations page approximately 30 minutes prior to the start of the conference call and webcast.

After the live webcast, the event will remain archived on the Aldeyra Therapeutics website for one year.

### **About Aldeyra Therapeutics**

Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead investigational drug product candidates are potential first-in-class treatments in development for dry eye disease, allergic conjunctivitis, proliferative vitreoretinopathy, and Sjögren-Larsson Syndrome. The company is also developing other product candidates for retinal and systemic inflammatory diseases.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20191202005925/en/>

Source: Aldeyra Therapeutics, Inc.

### **Corporate Contact:**

David McMullin  
Aldeyra Therapeutics, Inc.  
781-761-4904 ext. 218  
[dmcnullin@aldeyra.com](mailto:dmcnullin@aldeyra.com)

### **Investor & Media Contact:**

Scott Solomon  
Sharon Merrill Associates, Inc.  
617-542-5300  
[ALDX@investorrelations.com](mailto:ALDX@investorrelations.com)